Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema

Peter A Campochiaro, David M. Brown, Andrew Pearson, Thomas Ciulla, David Boyer, Frank G. Holz, Michael Tolentino, Amod Gupta, Lilianne Duarte, Steven Madreperla, John Gonder, Barry Kapik, Kathleen Billman, Frances E. Kane

Research output: Contribution to journalArticle

Abstract

Objective: To assess the efficacy and safety of intravitreal inserts releasing 0.2 μg/day (low dose) or 0.5 μg/day (high dose) fluocinolone acetonide (FA) in patients with diabetic macular edema (DME). Design: Two parallel, prospective, randomized, sham injection-controlled, double-masked, multicenter clinical trials. Participants: Subjects with persistent DME despite at least 1 macular laser treatment were randomized 1:2:2 to sham injection (n = 185), low-dose insert (n = 375), or high-dose insert (n = 393). Methods: Subjects received study drug or sham injection at baseline and after 6 weeks were eligible for rescue laser. Based on retreatment criteria, additional study drug or sham injections could be given after 1 year. Main Outcome Measures: The primary outcome was the percentage of patients with improvement from baseline best-corrected visual acuity (BCVA) in Early Treatment Diabetic Retinopathy Trial (ETDRS) letter score of 15 or more at month 24. Secondary outcomes included other parameters of visual function and foveal thickness (FTH). Results: The percentage of patients with improvement from baseline ETDRS letter score of 15 or more at month 24 was 28.7 and 28.6 in the low- and high-dose insert groups, respectively, compared with 16.2 in the sham group (P = 0.002 for each). Benefit occurred for both doses compared with sham at 3 weeks and all subsequent time points. The mean improvement in BCVA letter score between baseline and month 24 was 4.4 and 5.4 in the low- and high-dose groups, respectively, compared with 1.7 in the sham group (P = 0.02 and P = 0.016). At all time points compared with sham, there was significantly more improvement in FTH. Subjects requiring cataract surgery were more frequent in the insert groups, and their visual benefit was similar to that of subjects who were pseudophakic at baseline. Glaucoma requiring incisional surgery occurred in 3.7%, 7.6%, and 0.5% of the low-dose, high-dose, and sham groups, respectively. Conclusions: Both low- and high-dose FA inserts significantly improved BCVA in patients with DME over 2 years, and the risk-to-benefit ratio was superior for the low-dose insert. This is the first pharmacologic treatment that can be administered by an outpatient injection to provide substantial benefit in patients with DME for at least 2 years. Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references.

Original languageEnglish (US)
JournalOphthalmology
Volume118
Issue number4
DOIs
StatePublished - Apr 2011

Fingerprint

Fluocinolone Acetonide
Macular Edema
Injections
Visual Acuity
Disclosure
Lasers
Retreatment
Diabetic Retinopathy
Pharmaceutical Preparations
Glaucoma
Cataract
Multicenter Studies
Outpatients
Therapeutics
Outcome Assessment (Health Care)
Clinical Trials
Safety

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. / Campochiaro, Peter A; Brown, David M.; Pearson, Andrew; Ciulla, Thomas; Boyer, David; Holz, Frank G.; Tolentino, Michael; Gupta, Amod; Duarte, Lilianne; Madreperla, Steven; Gonder, John; Kapik, Barry; Billman, Kathleen; Kane, Frances E.

In: Ophthalmology, Vol. 118, No. 4, 04.2011.

Research output: Contribution to journalArticle

Campochiaro, PA, Brown, DM, Pearson, A, Ciulla, T, Boyer, D, Holz, FG, Tolentino, M, Gupta, A, Duarte, L, Madreperla, S, Gonder, J, Kapik, B, Billman, K & Kane, FE 2011, 'Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema', Ophthalmology, vol. 118, no. 4. https://doi.org/10.1016/j.ophtha.2010.12.028
Campochiaro, Peter A ; Brown, David M. ; Pearson, Andrew ; Ciulla, Thomas ; Boyer, David ; Holz, Frank G. ; Tolentino, Michael ; Gupta, Amod ; Duarte, Lilianne ; Madreperla, Steven ; Gonder, John ; Kapik, Barry ; Billman, Kathleen ; Kane, Frances E. / Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. In: Ophthalmology. 2011 ; Vol. 118, No. 4.
@article{69a05ca33c424dc0bd77a7806b565d8a,
title = "Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema",
abstract = "Objective: To assess the efficacy and safety of intravitreal inserts releasing 0.2 μg/day (low dose) or 0.5 μg/day (high dose) fluocinolone acetonide (FA) in patients with diabetic macular edema (DME). Design: Two parallel, prospective, randomized, sham injection-controlled, double-masked, multicenter clinical trials. Participants: Subjects with persistent DME despite at least 1 macular laser treatment were randomized 1:2:2 to sham injection (n = 185), low-dose insert (n = 375), or high-dose insert (n = 393). Methods: Subjects received study drug or sham injection at baseline and after 6 weeks were eligible for rescue laser. Based on retreatment criteria, additional study drug or sham injections could be given after 1 year. Main Outcome Measures: The primary outcome was the percentage of patients with improvement from baseline best-corrected visual acuity (BCVA) in Early Treatment Diabetic Retinopathy Trial (ETDRS) letter score of 15 or more at month 24. Secondary outcomes included other parameters of visual function and foveal thickness (FTH). Results: The percentage of patients with improvement from baseline ETDRS letter score of 15 or more at month 24 was 28.7 and 28.6 in the low- and high-dose insert groups, respectively, compared with 16.2 in the sham group (P = 0.002 for each). Benefit occurred for both doses compared with sham at 3 weeks and all subsequent time points. The mean improvement in BCVA letter score between baseline and month 24 was 4.4 and 5.4 in the low- and high-dose groups, respectively, compared with 1.7 in the sham group (P = 0.02 and P = 0.016). At all time points compared with sham, there was significantly more improvement in FTH. Subjects requiring cataract surgery were more frequent in the insert groups, and their visual benefit was similar to that of subjects who were pseudophakic at baseline. Glaucoma requiring incisional surgery occurred in 3.7{\%}, 7.6{\%}, and 0.5{\%} of the low-dose, high-dose, and sham groups, respectively. Conclusions: Both low- and high-dose FA inserts significantly improved BCVA in patients with DME over 2 years, and the risk-to-benefit ratio was superior for the low-dose insert. This is the first pharmacologic treatment that can be administered by an outpatient injection to provide substantial benefit in patients with DME for at least 2 years. Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references.",
author = "Campochiaro, {Peter A} and Brown, {David M.} and Andrew Pearson and Thomas Ciulla and David Boyer and Holz, {Frank G.} and Michael Tolentino and Amod Gupta and Lilianne Duarte and Steven Madreperla and John Gonder and Barry Kapik and Kathleen Billman and Kane, {Frances E.}",
year = "2011",
month = "4",
doi = "10.1016/j.ophtha.2010.12.028",
language = "English (US)",
volume = "118",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema

AU - Campochiaro, Peter A

AU - Brown, David M.

AU - Pearson, Andrew

AU - Ciulla, Thomas

AU - Boyer, David

AU - Holz, Frank G.

AU - Tolentino, Michael

AU - Gupta, Amod

AU - Duarte, Lilianne

AU - Madreperla, Steven

AU - Gonder, John

AU - Kapik, Barry

AU - Billman, Kathleen

AU - Kane, Frances E.

PY - 2011/4

Y1 - 2011/4

N2 - Objective: To assess the efficacy and safety of intravitreal inserts releasing 0.2 μg/day (low dose) or 0.5 μg/day (high dose) fluocinolone acetonide (FA) in patients with diabetic macular edema (DME). Design: Two parallel, prospective, randomized, sham injection-controlled, double-masked, multicenter clinical trials. Participants: Subjects with persistent DME despite at least 1 macular laser treatment were randomized 1:2:2 to sham injection (n = 185), low-dose insert (n = 375), or high-dose insert (n = 393). Methods: Subjects received study drug or sham injection at baseline and after 6 weeks were eligible for rescue laser. Based on retreatment criteria, additional study drug or sham injections could be given after 1 year. Main Outcome Measures: The primary outcome was the percentage of patients with improvement from baseline best-corrected visual acuity (BCVA) in Early Treatment Diabetic Retinopathy Trial (ETDRS) letter score of 15 or more at month 24. Secondary outcomes included other parameters of visual function and foveal thickness (FTH). Results: The percentage of patients with improvement from baseline ETDRS letter score of 15 or more at month 24 was 28.7 and 28.6 in the low- and high-dose insert groups, respectively, compared with 16.2 in the sham group (P = 0.002 for each). Benefit occurred for both doses compared with sham at 3 weeks and all subsequent time points. The mean improvement in BCVA letter score between baseline and month 24 was 4.4 and 5.4 in the low- and high-dose groups, respectively, compared with 1.7 in the sham group (P = 0.02 and P = 0.016). At all time points compared with sham, there was significantly more improvement in FTH. Subjects requiring cataract surgery were more frequent in the insert groups, and their visual benefit was similar to that of subjects who were pseudophakic at baseline. Glaucoma requiring incisional surgery occurred in 3.7%, 7.6%, and 0.5% of the low-dose, high-dose, and sham groups, respectively. Conclusions: Both low- and high-dose FA inserts significantly improved BCVA in patients with DME over 2 years, and the risk-to-benefit ratio was superior for the low-dose insert. This is the first pharmacologic treatment that can be administered by an outpatient injection to provide substantial benefit in patients with DME for at least 2 years. Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references.

AB - Objective: To assess the efficacy and safety of intravitreal inserts releasing 0.2 μg/day (low dose) or 0.5 μg/day (high dose) fluocinolone acetonide (FA) in patients with diabetic macular edema (DME). Design: Two parallel, prospective, randomized, sham injection-controlled, double-masked, multicenter clinical trials. Participants: Subjects with persistent DME despite at least 1 macular laser treatment were randomized 1:2:2 to sham injection (n = 185), low-dose insert (n = 375), or high-dose insert (n = 393). Methods: Subjects received study drug or sham injection at baseline and after 6 weeks were eligible for rescue laser. Based on retreatment criteria, additional study drug or sham injections could be given after 1 year. Main Outcome Measures: The primary outcome was the percentage of patients with improvement from baseline best-corrected visual acuity (BCVA) in Early Treatment Diabetic Retinopathy Trial (ETDRS) letter score of 15 or more at month 24. Secondary outcomes included other parameters of visual function and foveal thickness (FTH). Results: The percentage of patients with improvement from baseline ETDRS letter score of 15 or more at month 24 was 28.7 and 28.6 in the low- and high-dose insert groups, respectively, compared with 16.2 in the sham group (P = 0.002 for each). Benefit occurred for both doses compared with sham at 3 weeks and all subsequent time points. The mean improvement in BCVA letter score between baseline and month 24 was 4.4 and 5.4 in the low- and high-dose groups, respectively, compared with 1.7 in the sham group (P = 0.02 and P = 0.016). At all time points compared with sham, there was significantly more improvement in FTH. Subjects requiring cataract surgery were more frequent in the insert groups, and their visual benefit was similar to that of subjects who were pseudophakic at baseline. Glaucoma requiring incisional surgery occurred in 3.7%, 7.6%, and 0.5% of the low-dose, high-dose, and sham groups, respectively. Conclusions: Both low- and high-dose FA inserts significantly improved BCVA in patients with DME over 2 years, and the risk-to-benefit ratio was superior for the low-dose insert. This is the first pharmacologic treatment that can be administered by an outpatient injection to provide substantial benefit in patients with DME for at least 2 years. Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references.

UR - http://www.scopus.com/inward/record.url?scp=79953329178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953329178&partnerID=8YFLogxK

U2 - 10.1016/j.ophtha.2010.12.028

DO - 10.1016/j.ophtha.2010.12.028

M3 - Article

VL - 118

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 4

ER -